Business
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO Internatio...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016\nCanada NewsWire\nCALGARY, June 2, 2016\n\n\n\nCALGARY, June 2, 2016 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) is pleased to announce that findings of a study performed by the Baker IDI Heart and Diabetes Institute and Resverlogix has been published in the journal 'Metabolism', titled: \"Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.\"\n\nApabetalone Published In 'Metabolism' Journal\n\nData summarized in the publication was gathered from patients with prediabetes mellitus characterized by abnormal blood glucose levels. Treatment with apabetalone/RVX-208 (200 mg/day) for 29-33 days led to not only a reduction in glucose absorption but also suppression of endogenous glucose production. The significance of these findings are as follows: (1) short duration of RVX-208 treatment had effects on glucose metabolism, and (2) both the reduction in glucose absorption and production are expected to be of benefit in patients with prediabetes mellitus. \n\nBio International 2016 Presentation\n\nResverlogix also announces that Mr. Donald McCaffrey, President and Chief Executive Officer is scheduled to present at BIO International 2016, in San Francisco, CA, in which a corporate update will be provided.\n\nDate: Tuesday, June 7, 2016Time: 11:15 am PDT / 2:15 pm EDT\n\nWe invite interested parties to visit: http://www.veracast.com/webcasts/bio/internationalconvention2016/37214271955.cfm at the presentation time noted above to listen to the live webcast. \n\nA replay will be available one hour after the live presentation and may be accessed via the same link above. The archived webcast will be available until September 5, 2016. \n\nAbout Resverlogix\n\nResverlogix is developing apabetalone (RVX-208), a ...